SynAct Pharma: New Indication Provides Diversification - Redeye
Redeye updates its base case of Synact following the directed share issue and new programme in polymyalgia rheumatica, which broadens resomelagon’s potential and diversifies its clinical development risk.
ANNONS
Redeye updates its base case of Synact following the directed share issue and new programme in polymyalgia rheumatica, which broadens resomelagon’s potential and diversifies its clinical development risk.